Adjuvant therapy for colon cancer Journal Article
| Author: | Saltz, L. B. |
| Article Title: | Adjuvant therapy for colon cancer |
| Abstract: | Patients are not at risk of dying from a tumor that has been removed; they are at risk of dying from residual microscopic disease not removed at the time of operation. Thus, the goal of an adjuvant treatment, be it chemotherapy, radiation therapy, immunotherapy, or dietary and lifestyle manipulations, is to eradicate any residual, albeit microscopic, metastatic disease that might remain. Stage I disease carries an excellent prognosis, and at present there are no compelling data to support adjuvant chemotherapy for patients with this early stage. Stage II colon cancer also has a good prognosis after operation alone and represents the most complicated and contentious area in decisions regarding the use of adjuvant chemotherapy. Stage III colorectal cancer (TanyN1-2M0) represents a group at a higher risk of recurrence, and this population is routinely given adjuvant chemotherapy in the absence of a medical or psychiatric contraindication. © 2010 Elsevier Inc. |
| Keywords: | disease-free survival; clinical trial; neutropenia; review; cancer recurrence; bevacizumab; fluorouracil; placebo; cancer combination chemotherapy; diarrhea; drug efficacy; hypertension; clinical trials as topic; disease marker; capecitabine; adjuvant therapy; cancer adjuvant therapy; chemotherapy, adjuvant; radiotherapy, adjuvant; cancer staging; neurotoxicity; recurrence risk; antineoplastic agent; neoplasm staging; colorectal cancer; multiple cycle treatment; sensory neuropathy; antineoplastic combined chemotherapy protocols; dehydration; colonic neoplasms; cetuximab; irinotecan; febrile neutropenia; immunotherapy; folinic acid; colon cancer; microsatellite instability; drug response; oxaliplatin; digestive system perforation; proteinuria; artery thrombosis; colon surgery; levamisole; uft; 5-fluorouracilu |
| Journal Title: | Surgical Oncology Clinics of North America |
| Volume: | 19 |
| Issue: | 4 |
| ISSN: | 1055-3207 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2010-10-01 |
| Start Page: | 819 |
| End Page: | 827 |
| Language: | English |
| DOI: | 10.1016/j.soc.2010.07.005 |
| PUBMED: | 20883956 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Export Date: 20 April 2011" - "CODEN: SOCAF" - "Source: Scopus" |
